EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Diverse Neuromuscular Spectrum of VPS13A Disease

Anne Buchberger iD, Evamaria Riedel iD, Marie Hackenberg, Alexander Mensch iD, Stefanie Beck-Woedl, Joohyun Park iD, Tobias B Haack, Bernhard Haslinger, Jan Kirschke iD, Holger Prokisch iD, Andreas Hermann iD, Christian Mawrin und 5 weitere

Annals of Clinical and Translational Neurology · 2026

DOI: 10.1002/acn3.70198 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2026. Verfasst von Anne Buchberger und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany. Hauptthemen laut MEDLINE: Neuroacanthocytosis, Vesicular Transport Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Advocacy for Neuroacanthocytosis Patients, EMINA network, Else Kröner-Fresenius-Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

VPS13A disease (chorea‐acanthocytosis) is a rare neurodegenerative disorder caused by biallelic variants in VPS13A, typically presenting with hyperkinetic movement disorders, while neuromuscular signs are often mild. The aim of the project was to investigate the frequency and severity of neuromuscular impairment in VPS13A disease.

Methods

We systematically assessed the neuromuscular involvement in six patients with VPS13A disease. Our evaluation included genetic and clinical data, blood tests, electrophysiological studies, muscle MRI, and tissue samples from muscle and nerve.

Results

Age at clinical onset was 14 to 38 years (median: 37.5). Age at onset of paresis was 27 to 29 years (median: 29). Initial symptoms included seizures (5/6), hyperkinesia (2/6), and muscle weakness (1/6). Neuromuscular signs ranged from hyporeflexia (5/6) to progressive muscle wasting (3/6). Nine VPS13A variants were detected, including a novel copy‐neutral inversion. Phosphocreatine kinase was elevated in all cases (498–12,420 U/L; median of highest values: 2230 U/L). Nerve conduction studies revealed sensorimotor axonal neuropathy. Electromyography showed chronic neurogenic changes with high amplitudes, polyphasic potentials, and reduced interference patterns (6/6). Muscle MRI displayed fatty atrophy, most prominently in the calves (5/5). Muscle histology indicated neurogenic and myopathic changes. Electron microscopy of mitochondria and respiratory chain analysis showed no specific pathological findings.

Interpretation

Our findings emphasize the underrecognized neuromuscular spectrum in VPS13A disease, ranging from subclinical signs to severe paresis and sometimes preceding the hyperkinesia that gave rise to the historical term of chorea‐acanthocytosis. A comprehensive understanding of the phenotype is crucial for early diagnosis and appropriate management of VPS13A disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroacanthocytosisVesicular Transport ProteinsHumansAdultMaleFemaleYoung AdultAdolescent

Substanzen

VPS13A protein, humanVesicular Transport Proteins

Autor:innen und Institutionen

  • Department of Neurology, University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
  • Department of Neuroradiology, University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
  • Department of Neurology, Martin Luther University Halle-Wittenberg and University Hospital Halle, Halle (Saale), Germany.
  • Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
  • Center for Rare Diseases, University of Tübingen, Tübingen, Germany.
  • Institute of Human Genetics, University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.

ORCID-Profile: Anne Buchberger, Evamaria Riedel, Alexander Mensch, Joohyun Park, Jan Kirschke, Holger Prokisch, Andreas Hermann

Förderung

  • Advocacy for Neuroacanthocytosis Patients
  • EMINA network
  • Else Kröner-Fresenius-Stiftung
  • German Research Foundation (Deutsche Forschungsgemeinschaft) (DFG)
  • European Research Council (ERC)
  • Federal Ministry of Education and Research (BMBF)
  • Hermann and Lilly Schilling-Foundation ("Hermann und Lilly Schilling-Stiftung für medizinische Forschung")
  • Federal Ministry of Education and Research (BMBF)/VDI

Zitieren

APA

Buchberger, A., Riedel, E., Hackenberg, M., Mensch, A., Beck-Woedl, S., Park, J., Haack, T. B., Haslinger, B., Kirschke, J., Prokisch, H., Hermann, A., Mawrin, C., Danek, A., Schoser, B., Peikert, K., Deschauer, M., & Cordts, I. (2026). The Diverse Neuromuscular Spectrum of VPS13A Disease. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70198

Vancouver

Buchberger A, Riedel E, Hackenberg M, Mensch A, Beck-Woedl S, Park J, et al. The Diverse Neuromuscular Spectrum of VPS13A Disease. Annals of Clinical and Translational Neurology. 2026. doi:10.1002/acn3.70198

BibTeX
@article{Buchberger2026,
  author = {Buchberger, Anne and Riedel, Evamaria and Hackenberg, Marie and Mensch, Alexander and Beck-Woedl, Stefanie and Park, Joohyun and Haack, Tobias B and Haslinger, Bernhard and Kirschke, Jan and Prokisch, Holger and Hermann, Andreas and Mawrin, Christian and Danek, Adrian and Schoser, Benedikt and Peikert, Kevin and Deschauer, Marcus and Cordts, Isabell},
  title = {The Diverse Neuromuscular Spectrum of VPS13A Disease},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  doi = {10.1002/acn3.70198}
}
Kostenlos starten →